Allogene activates three cancer centers as first sites for Phase 2 ALPHA3 trial

Allogene Therapeutics announced that Rocky Mountain Cancer Centers, part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, a multi-specialty community oncology practice and part of the OneOncology network; and Norton Cancer Institute, are open for enrollment in the pivotal Phase 2 ALPHA3 trial. The ALPHA3 trial is evaluating the use of cemacabtagene ansegedleucel as part of the first line consolidation treatment regimen for newly diagnosed and treated large B-cell lymphoma patients who remain positive for minimal residual disease. Detection of MRD will be done using the Foresight CLARITY Investigational Use Only MRD test, powered by PhasED-Seq. When given as a “7th cycle” of frontline treatment to eligible patients with MRD, consolidation treatment with cema-cel has the potential to meaningfully improve 1L cure rates for patients with LBCL who are likely to relapse.